Showing 1 - 10 of 579
On innovation grounds, pharmaceutical patents are unnecessary in low income populations, since such markets cannot do much to support global pharmaceutical profits. The public health needs of low income populations require patented drugs to be manufactured at the marginal cost of production,...
Persistent link: https://www.econbiz.de/10014057600
Penicillin and other antibiotics were the original wonder drugs and laid the foundation of the modern pharmaceutical industry. Human health significantly improved with the introduction of antibiotics. By 1967, the US Surgeon General declared victory over infectious diseases in the US. But pride...
Persistent link: https://www.econbiz.de/10014060278
While the recent WTO agreement allowing developing countries to import life-saving drugs by bypassing patent laws is beneficial, a majority of the drugs used to combat epidemics are off-patent or not patented in many developing countries. Consequently, the agreement will do very little to assist...
Persistent link: https://www.econbiz.de/10014069834
While neoclassical economic theory suggests that arbitrage will undermine global differential pricing of pharmaceuticals, the empirical results are more complex. Pharmaceutical regulation, IP laws, global trade agreements, and company policies support differential pricing despite the pressure of...
Persistent link: https://www.econbiz.de/10014070573
The US government has embarked on a trade strategy to address alleged free riding by raising patented prescription drug prices abroad. This strategy is unwise and dangerous. It is likely to 'succeed' in low and middle income countries, desperate to sign a bilateral trade agreement with the US....
Persistent link: https://www.econbiz.de/10014065505
Forty percent of spiraling US drug costs are based on a mere two percent of all drugs –biologic drugs (biologics) made from living cells that are administered by injection or infusion. These costs will continue to balloon as new biologics are approved; the recently approved Alzheimer’s drug is...
Persistent link: https://www.econbiz.de/10014087594
Persistent link: https://www.econbiz.de/10011338824
This volume is part of the response to the 2016 UN General Assembly Special Session (UNGASS) on international drug policy and the emergence of analysis of international drug policy in academic literature. Editors David Bewley-Taylor and Khalid Tinasti, both respected authors in their own right,...
Persistent link: https://www.econbiz.de/10013197684
Persistent link: https://www.econbiz.de/10012433988
Persistent link: https://www.econbiz.de/10013445113